Researchers have developed EVScape, a predictive tool that identifies which SARS-CoV-2 strains are most likely to evade host immunity. Utilizing a deep generative model and structural information, the tool offers early warning about viral variants, aiding in the timely development of effective vaccines and treatments.
SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.
February 20, 2024